Arbor Biotechnologies
PrivateLast Round
Series C
Mar 18, 2025
Est. Valuation
$575M
Total Funding Raised
$304.5M
Company Overview
Arbor Biotechnologies operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series C round in March 2025.
Arbor Biotechnologies is a biotechnology company that develops genomic medicines and gene-editing tools using AI and machine learning to address genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arbor Biotechnologies Comparables
Compare Arbor Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Scribe Therapeutics | 85% | |
| Tessera Therapeutics | 79% | |
| HuidaGene Therapeutics | 79% |
For institutional investors. Book with your work email.
Arbor Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 18, 2025 | ||||
| Series B | Nov 9, 2021 | ||||
| Series A | Aug 2, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Arbor Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GreatPoint Ventures | Series B |
| S32 | Series B |
| Surveyor Capital | Series C, Series B |
| Janus Henderson Group | Series B |
| Aberdeen Group plc | Series C |
| Temasek | Series C, Series B |
| TCG Crossover | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
Monthly visitors increased 79% MoM.
- Mar 1, 2026
Lead program ABO-101 enters clinical trials for primary hyperoxaluria type 1.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 21, 2026
On Oct 21st '26, Arbor hires Albert Misko, M.D., Ph.D., a board-certified neurologist, as Vice President, Head of Clinical Development, where he leads clinical development for the CNS portfolio.
- adopts_technologyOct 21, 2026
Arbor uses Quilt’s Benchling Packager as the standard route for pre-clinical data, linking datasets to experimental records and making cross-assay analysis faster; it has run a Quilt catalog since 2023.
For institutional investors. Book with your work email.
Arbor Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Arbor Biotechnologies's valuation, stock price, and market status.
Is Arbor Biotechnologies a public or private company?
Arbor Biotechnologies is a private company.
What is the current stock price of Arbor Biotechnologies?
Arbor Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Arbor Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Arbor Biotechnologies worth (valuation)?
Arbor Biotechnologies's valuation is estimated at $575.0M based on funding round data.
Can I buy Arbor Biotechnologies stock?
Arbor Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Arbor Biotechnologies's last funding round?
Arbor Biotechnologies's most recent funding round was Series C on March 18, 2025.
Who are the main investors in Arbor Biotechnologies?
Key investors in Arbor Biotechnologies include Temasek, TCG Crossover, Ally Bridge Group, ARCH Venture Partners.
Will Arbor Biotechnologies IPO soon?
No public IPO plans have been announced for Arbor Biotechnologies.
How can I track Arbor Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Arbor Biotechnologies's shares on secondary markets.